GlassScriptPhysician profile
Diane S Chiu
NPI 1699736843
$4,648.64
in general payments reported to CMS, 2019-2025
21 companies · $501 in 2025
The $501 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $324 · 2021: $321 · 2022: $501 · 2023: $836 · 2024: $1,264 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,599.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,512.71 | 2019-2025 | Botox, Rinvoq |
| Galderma Laboratories, L.P. | $719.85 | 2019-2025 | Dysport |
| Allergan, INC. | $627.38 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $396.29 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $232.98 | 2023-2024 | Sotyktu |
| Ucb, INC. | $231.68 | 2022-2024 | Bimzelx |
| Incyte Corporation | $165.19 | 2022-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $157.34 | 2019-2024 | Dupixent |
| Almirall LLC | $128.70 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $88.52 | 2025 | Levulan Kerastick |
| Amgen INC. | $70.43 | 2022-2024 | Otezla |
| Genzyme Corporation | $58.86 | 2019 | |
| Pfizer INC. | $52.76 | 2019 | |
| Dermavant Sciences, INC. | $39.93 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $39.07 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $38.11 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $23.83 | 2020 | |
| Prugen, INC. Pharmaceuticals | $20.66 | 2019 | |
| Biofrontera INC. | $16.09 | 2024 | Rhodoled Xl, Ameluz, Xepi |
| Merck Sharp & Dohme LLC | $14.29 | 2019 | |
| Lilly USA, LLC | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Chiu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.